Back to Search Start Over

Clinical outcomes of Chronic Myeloid Leukaemia (CML) patients on asciminib through the Managed Access Program (MAP) in Australia

Authors :
Lynette C.Y. Chee
Nora Lee
Andrew Grigg
Melissa Chen
Anthony Schwarer
Jeff Szer
David T Yeung
Timothy Hughes
Naranie Shanmuganathan
Chee, Lynette CY
Lee, Nora
Grigg, Andrew
Chen, Melissa
Schwarer, Anthony
Szer, Jeff
Yeung, David T
Hughes, Timothy
Shanmuganathan, Naranie
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) New Orleans, US 10-13 December 2022
Publication Year :
2022
Publisher :
US : American Society of Hematology, 2022.

Abstract

Asciminib is the first tyrosine kinase inhibitor (TKI) to Specifically Target the ABL Myristoyl Pocket (STAMP). In the ASCEMBL Phase 3 randomised study comparing asciminib to bosutinib in patients with CML in chronic phase (CP) after ³2 prior TKIs, asciminib demonstrated superior efficacy and tolerability vs bosutinib (major molecular response (MMR) rate at week 96: 37.6% vs 15.8%, treatment discontinuation 7.7% vs 26.3%) (Rea et al, EHA 2022). Here we present the real-world clinical outcomes of TKI-resistant/ intolerant CML patients in Australia who received asciminib through a MAP approved by Novartis.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....8fbeb9274c847e80c9e4b44851795fd5